References
- Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 2010;121:e46–215
- Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–34
- Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434–44
- Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117–25
- Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39
- Standards of medical care in diabetes–2011. Diabetes Care 2011;34(Suppl 1):S11–61
- Cheung BM, Ong KL, Cherny SS, et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009;122:443–53
- Mann DM, Woodward M, Ye F, et al. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors. Arch Intern Med 2009;169:1718–20
- van den HP, Heintjes E, Plat AW, et al. Determination of non-treatment with statins of high risk patients in The Netherlands. Curr Med Res Opin 2010;26:271–8
- Malik S, Lopez V, Chen R, et al. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract 2007;77:126–33
- Charpentier G, Genes N, Vaur L, et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey. Diabetes Metab 2003;29:152–8
- Robinson JG, Booth B. Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. J Clin Lipidol 2010;4:483–90
- Pyorala K, Lehto S, De Bacquer D, et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys. Diabetologia 2004;47:1257–65
- Standards of medical care in diabetes–2008. Diabetes Care 2008;31(Suppl 1):S12–54
- Oderda G, Lieberman M, Asche C, et al. Use of electronic medical record (EMR) data in outcomes research. Value Health 2007;10:A450–1
- Steinberg BA, Braganza AJ, Eminowicz G, et al. Are statins being underdosed in clinical practice? Data from TACTICS-TIMI 18. Crit Pathw Cardiol 2005;4:169–73
- Ruokoniemi P, Korhonen MJ, Helin-Salmivaara A, et al. Statin adherence and the risk of major coronary events in patients with diabetes a nested case-control study. Br J Clin Pharmacol 2010; doi: 10.1111/j.1365-2125.2010.03895.x. [Epub ahead of print]
- Donnelly LA, Doney AS, Morris AD, et al. Long-term adherence to statin treatment in diabetes. Diabet Med 2008;25:850–5
- AB E, Denig P, van Vliet T, Dekker JH. Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: a qualitative study. BMC Fam Pract 2009;10:24
- Tsang JL, Mendelsohn A, Tan MK, et al. Discordance between physicians' estimation of patient cardiovascular risk and use of evidence-based medical therapy. Am J Cardiol 2008;102:1142–5
- Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. QJM 2010;104:109–24
- Lardizabal JA, Deedwania PC. Benefits of statin therapy and compliance in high risk cardiovascular patients. Vasc Health Risk Manag 2010;6:843–53